Navigation Links
Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
Date:4/22/2010

HAIKOU, China, April 22 /PRNewswire-Asia-FirstCall/ -- Kun Run Biotechnology, Inc. (the "Company" or "Kun Run") (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides, peptide-based drugs and small molecule drugs, today announced the signing of a private placement agreement totaling approximately US$8 million of preferred stock and warrants with Caduceus Asia Partners, L.P., an investment fund managed by OrbiMed Advisors, LLC, and Mr. Xueyun Cui, the Chairman of the Company's Board of Directors and the majority stockholder of the Company.

"We are extremely pleased to have OrbiMed as Kun Run's first institutional investor, marking an important milestone in our company's progress," stated Mr. Cui. "We believe OrbiMed has a distinguished reputation and strong track record in healthcare fund management with a global network that enables our Company access to opportunities in the overseas pharmaceutical market. We believe that our company's strong foundation in peptides, peptide-based drugs and small molecule drugs, along with OrbiMed's credibility in the healthcare space, will result in continued growth and return for our shareholders."

Dr. Nancy T. Chang, Chairman and Senior Managing Director of OrbiMed's Caduceus Asia Partners Fund, will join the board of Kun Run in connection with this transaction. "We are enthusiastic about the Chinese pharmaceutical market and are excited to see quality companies like Kun Run emerge in this market," said Dr. Chang.

The net proceeds will primarily be used for potential acquisitions of drug products and pipeline assets and working capital needs.

The Company intends to file a Current Report on Form 8-K with the Securities and Exchange Commission today, which will include a more detailed description of the transaction.

About Kun Run Biotechnology Inc

Kun Run Biotechnology, Inc., together with its subsidiaries, engages in manufacture and sale of polypeptide medicines. It uses solid phase peptide synthesis (SPPS) and advanced purifying technology to produce various therapeutic polypeptide drugs, of which is "TP-5" most known for efficiently regulating humans' immune systems in order to defend and cure malignant diseases. The company maintains two state-of-art manufacturing plants and possesses one of the largest peptide synthesizing capacities across Asia.

About OrbiMed Advisors

OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

OrbiMed's investment team includes over 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. The firm's diverse team of professionals has a unique understanding of industry dynamics through active participation in both public and private companies. Our professionals work together in a collaborative, team-oriented approach which seamlessly integrates our public and private equity platforms. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. Where appropriate, particularly within its venture capital funds, OrbiMed supports its portfolio companies in achieving strategic, financial and operational objectives via participation at the Board of Directors level. OrbiMed professionals currently serve on the Board of Directors of dozens of different life sciences companies. For more information, please visit: http://www.orbimed.com/

Safe Harbor Statement

This release contains certain "forward-looking statements" relating to the business of Kun Run Biotechnology, Inc. and its subsidiary companies. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, concentration in a single customer, raw material costs, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. Kun Run Biotechnology, Inc. is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.


'/>"/>
SOURCE Kun Run Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
2. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
3. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
4. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc.
7. Arigene Co., Ltd. Announces Termination of Tender Offer To Purchase and Return of Validly Tendered Shares of Common Stock of Trimeris, Inc.
8. LifeSync Purchases Wireless Patent Portfolio from Motorola
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
11. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , Jan. 18, 2017 ... 2022 Summary GlobalData,s new report, "South Korea ... data on the South Korea Insulin Delivery market. The ... (in units) and average prices (USD) within market segments ... Insulin Pump Accessories. The report also provides company ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... "Breast Imaging Technologies Market by Type: Global Opportunity Analysis and ... market size was valued at $2,544 million in 2015 and ... a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. Ionizing ...
(Date:1/18/2017)... Calif. , Jan. 18, 2017  Adaptive Sound Technologies, ... today a new partnership with Hyatt Place Nashville/Downtown to ... providing ASTI LectroFan sleep therapy machines in over two ... of the most important parts of having a great ... general manager of Hyatt Place Nashville/Downtown. "We,re pleased to ...
Breaking Medicine Technology:
(Date:1/19/2017)... Los Angeles, California (PRWEB) , ... January 19, ... ... at the hands of a doctor who administered fillers that resulted in severe ... her unprecedented case was taken on by doctors at UCLA Medical Center, who ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Tranquility acoustic and privacy panel system. , The Tranquility privacy panel system ... a collaborative office environment. Tranquility panels help reduce noise and provide the visual ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sam & Associates Insurance Agency, a full service ... in the California Bay Area, is launching a charity drive to raise awareness of ... disease is the primary killer of adult men and women in America, and is ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the third ... New Jersey and the surrounding area, is inaugurating a charity event to ... commonly known as Lou Gehrig's disease or motor neurone disease, is a deadly ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... the 2017 Spring Create Real Impact contest from Impact Teen Drivers and California ... http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded for ...
Breaking Medicine News(10 mins):